At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
Copanlisib (BAY 80-6946)drug
Likely dose
Copanlisib (BAY 80-6946) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
In Brief
A Phase 3 clinical trial evaluating Copanlisib (BAY 80-6946) for Lymphoma, Non-Hodgkin. Completed, enrolled 25 participants across 21 sites in 10 countries.
Detailed Summary
To assess the safety of copanlisib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin
CountriesBrazil, Bulgaria, Greece, Italy, Poland, Russia, South Africa, South Korea, Taiwan, Turkey (Türkiye)
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartSep 2015
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 23, 2015
Enrollment StartSep 22, 2015
Primary CompletionOct 26, 2022
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 11.4 years ago
Interventions
Copanlisib (BAY 80-6946)drug
60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle